2,129
Views
5
CrossRef citations to date
0
Altmetric
Articles

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up

, &
Pages 326-331 | Received 12 Jul 2020, Accepted 26 Nov 2020, Published online: 17 Jun 2021

References

  • Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779–786.
  • Eltabbakh GH, Piver MS, Hempling RE, et al. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.
  • Thomas A, Chen Y, Yu T, et al. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6:16766–16773.
  • Cioffredi L-A, Jänne PA, Jackman DM. Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer. 2009;52:127–129.
  • Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–4567.
  • Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–691.
  • Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–412.
  • Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute Experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, editor. Regional chemotherapy: clinical research and practice. Totowa (NJ): Humana Press; 2000. p. 127–150.
  • Talerman A, Montero JR, Chilcote RR, et al. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol. 1985;9:73–80.
  • Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–6242.
  • Sugalski A, Davis M, Prasannan L, et al. Clinical, histologic, and genetic features of mesothelioma in a 7-year-old child. Pediatr Blood Cancer. 2013;60:146–148.
  • Gutman SI, Steinherz PG, Gray GF. Malignant peritoneal mesothelioma in a child. Am J Dis Child. 1976;130:1268–1269.
  • Oberto C, Schwarz KB, Zambidis E, et al. Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease. Dig Dis Sci. 2004;49:434–437.
  • Haliloglu M, Hoffer FA, Fletcher BD. Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings. Pediatr Radiol. 2000;30:251–255.
  • Hayes-Jordan A, Green H, Ludwig J, et al. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer. 2012;59:395–397.
  • Dhir M, Ramalingam L, Shuai Y, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in adolescent and young adults with peritoneal metastases. Ann Surg Oncol. 2017;24:875–883.
  • Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21:1474–1479.
  • Kusamura S, Torres Mesa PA, Cabras A, et al. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1468–1473.